帶狀皰疹感染治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按治療類型、給藥途徑、按地區和競爭的配銷通路細分

2022 年全球帶狀皰疹感染治療市場價值為 2.4892 億美元，預計在預測期內將強勁成長，到 2028 年CAGR為4.39%。近年來，全球帶狀皰疹感染治療市場經歷了顯著的成長和轉型這是由人口老化、對帶狀皰疹感染的認知不斷提高以及醫學研究和治療方案的進步等綜合因素推動的。帶狀皰疹，俗稱帶狀皰疹，是由水痘帶狀皰疹病毒重新活化引起的病毒感染，最初會導致水痘。感染通常表現為疼痛的皮疹和水泡，如果處理不當，可能會導致長期併發症。因此，對帶狀皰疹感染治療的需求激增，導致市場蓬勃發展。

全球帶狀皰疹感染治療市場的關鍵驅動力之一是人口老化，因為由於免疫系統減弱，老年人更容易受到水痘帶狀皰疹病毒重新活化的影響。此外，人們對這種疾病、其潛在併發症以及有效治療方法的認知不斷提高，促使更多人儘早尋求醫療干預，從而促進了市場成長。

該市場的特點是有一系列的治療選擇，包括抗病毒藥物、止痛藥物和疫苗。阿昔洛韋、伐昔洛韋和泛昔洛韋等抗病毒藥物一直是帶狀皰疹感染治療的基石，及時服用有助於減輕症狀的嚴重程度和縮短症狀的持續時間。疼痛管理藥物，如鴉片類藥物和抗發炎藥物，在緩解帶狀皰疹相關的劇烈疼痛方面發揮著至關重要的作用。此外，Zostavax 和 Shingrix 等疫苗的推出徹底改變了帶狀皰疹感染的預防，特別是在老年人中。這些疫苗的需求強勁，為市場成長做出了重大貢獻。

市場概況
預測期	2024-2028
2022 年市場規模	24892萬美元
2028 年市場規模	3.2122億美元
2023-2028 年CAGR	4.39%
成長最快的細分市場	網路藥局
最大的市場	北美洲

主要市場促進因素

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 研究年份
  • 主要市場區隔

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要產業夥伴
• 主要協會和二手資料來源
• 預測方法
• 數據三角測量與驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況
• 市場促進因素、挑戰、趨勢概述

第 4 章：全球帶狀皰疹感染治療市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依治療類型（處方治療、支持性治療）
  • 依給藥途徑（口服、靜脈注射、其他）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類 (2022)
• 市場地圖
  • 按治療類型
  • 按治療
  • 依給藥途徑
  • 按配銷通路
  • 按地區

第 5 章：亞太地區帶狀皰疹感染治療市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 依給藥途徑
  • 按配銷通路
  • 按國家/地區
• 亞太地區：國家分析
  • 中國帶狀皰疹感染治療
  • 印度帶狀皰疹感染治療
  • 澳洲帶狀皰疹感染治療
  • 日本帶狀皰疹感染治療
  • 韓國帶狀皰疹感染治療

第 6 章：歐洲帶狀皰疹感染治療市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 依給藥途徑
  • 按配銷通路
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 7 章：北美帶狀皰疹感染治療市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 按配銷通路
  • 依給藥途徑
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第 8 章：南美洲帶狀皰疹感染治療市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 依給藥途徑
  • 按配銷通路
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 9 章：中東和非洲帶狀皰疹感染治療市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 依給藥途徑
  • 按配銷通路
  • 按國家/地區
• MEA：國家分析
  • 南非帶狀皰疹感染治療
  • 沙烏地阿拉伯 帶狀皰疹感染治療
  • 阿拉伯聯合大公國帶狀皰疹感染治療
  • 埃及 帶狀皰疹感染治療

第 10 章：市場動態

• 促進要素
• 挑戰

第 11 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 12 章：全球缺鐵性貧血：SWOT 分析

第 13 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第14章：競爭格局

• 葛蘭素史克公司
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Current Capacity Analysis
  • Financials (In case of listed)
  • Recent Developments
  • SWOT Analysis
• 博士健康公司
• 雷納塔有限公司
• 諾萬公司
• 美國梯瓦製藥公司
• 輝瑞公司
• 阿波泰克斯公司
• 山德士加拿大公司
• 諾華製藥公司。

第 15 章：策略建議

第 16 章：關於我們與免責聲明

Global Herpes Zoster Infection Treatment Market has valued at USD 248.92 million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 4.39% through 2028. The Global Herpes Zoster Infection Treatment Market has witnessed significant growth and transformation in recent years, driven by a combination of factors such as an aging population, increasing awareness about herpes zoster infection, and advancements in medical research and treatment options. Herpes zoster, commonly known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus, which initially causes chickenpox. The infection typically manifests as a painful rash and blisters, and it can lead to long-term complications if not managed effectively. As a result, the demand for herpes zoster infection treatment has surged, leading to a burgeoning market.

One of the key drivers of the global herpes zoster infection treatment market is the aging population, as older individuals are more susceptible to the reactivation of the varicella-zoster virus due to weakened immune systems. Additionally, heightened awareness about the condition, its potential complications, and the availability of effective treatments has prompted more individuals to seek medical intervention at an earlier stage, boosting market growth.

The market is characterized by a range of treatment options, including antiviral medications, pain management drugs, and vaccines. Antiviral medications like acyclovir, valacyclovir, and famciclovir have been the cornerstone of herpes zoster infection treatment, helping to reduce the severity and duration of symptoms when administered promptly. Pain management drugs, such as opioids and anti-inflammatory medications, play a crucial role in alleviating the excruciating pain associated with shingles. Furthermore, the introduction of vaccines like Zostavax and Shingrix has revolutionized herpes zoster infection prevention, particularly among older adults. These vaccines have witnessed robust demand, contributing significantly to market growth.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 248.92 Million
Market Size 2028	USD 321.22 Million
CAGR 2023-2028	4.39%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Key Market Drivers

Rising Aging Population

As individuals age, their immune systems weaken, making them more susceptible to the reactivation of this virus. This heightened susceptibility among the elderly population has led to a surge in the number of shingles cases worldwide. With a growing percentage of the global population entering their senior years, the incidence of herpes zoster infections has increased substantially. Older adults experiencing shingles often suffer from severe pain, discomfort, and complications, including postherpetic neuralgia (PHN), which is a persistent and debilitating pain condition. This heightened vulnerability and the potentially severe consequences of herpes zoster have prompted an increased demand for effective treatment options.

The aging demographic not only contributes to a rise in the number of herpes zoster cases but also influences patient behavior. Older individuals are generally more health-conscious and proactive about seeking medical attention when they experience symptoms, further driving the demand for herpes zoster infection treatment. Healthcare providers and pharmaceutical companies have recognized this growing need and have developed targeted treatments and prevention strategies to cater to this specific demographic, including antiviral medications, pain management drugs, and vaccines.

The aging population is a key factor in the expansion of the Global Herpes Zoster Infection Treatment Market. As the world's demographic profile continues to shift towards an older population, the incidence of shingles is expected to remain high, sustaining a consistent demand for effective treatments.

Increasing Awareness

Increasing awareness has emerged as a pivotal factor fueling the growth of the Global Herpes Zoster Infection Treatment Market. Herpes zoster, commonly referred to as shingles, is caused by the reactivation of the varicella-zoster virus, which initially causes chickenpox. Historically, lack of awareness and understanding about the condition often led to delayed diagnosis and inadequate treatment. However, in recent years, there has been a notable shift in both healthcare professionals' and the general public's awareness of herpes zoster, resulting in significant market expansion.

Healthcare professionals have become better equipped to identify and diagnose herpes zoster accurately. Continuous medical education and advancements in diagnostic tools have played a crucial role in improving the precision and speed of diagnosis. This has enabled healthcare providers to recommend timely and effective treatments, leading to better outcomes for patients. Moreover, the ability to promptly recognize herpes zoster reduces the risk of complications such as postherpetic neuralgia (PHN), a persistent and debilitating pain condition that can follow shingles.

On the patient side, increased awareness has empowered individuals to recognize the symptoms of herpes zoster and seek early medical intervention. As people become more informed about the condition and its potential complications, they are more likely to consult healthcare professionals when they experience shingles symptoms. This proactive approach to healthcare has resulted in higher demand for treatments, as patients are eager to alleviate the pain and discomfort associated with herpes zoster and prevent long-term complications.

Awareness campaigns, both by healthcare organizations and pharmaceutical companies, have played a vital role in disseminating information about herpes zoster. These campaigns have not only educated the public about the condition but also highlighted the importance of early diagnosis and appropriate treatment. Consequently, patients are now more motivated to actively participate in their healthcare journey, further propelling the demand for herpes zoster infection treatment.

Advancements in Treatment Options

Advancements in treatment options have significantly propelled the growth of the Global Herpes Zoster Infection Treatment Market. Herpes zoster, commonly known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus, and the availability of improved treatments has revolutionized the management of this condition.

Antiviral medications have been a cornerstone in herpes zoster treatment. Drugs like acyclovir, valacyclovir, and famciclovir have proven highly effective in reducing the severity and duration of symptoms when administered promptly after diagnosis. These medications inhibit viral replication and help patients recover more quickly. Advancements in antiviral therapy, including novel formulations and improved dosing regimens, have enhanced treatment efficacy, leading to better outcomes for patients.

Pain management is another critical aspect of herpes zoster treatment, given the excruciating pain and discomfort associated with the condition. Advancements in this area have led to more effective pain relief strategies. Opioid analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), and topical agents have all played vital roles in alleviating the suffering of individuals with shingles. Additionally, innovations in pain management techniques, such as nerve blocks and regional anesthesia, have provided further options for reducing pain, particularly in cases of postherpetic neuralgia (PHN).

Vaccination has been a game-changer in herpes zoster infection prevention. The introduction of vaccines like Zostavax and Shingrix has not only reduced the incidence of shingles but has also spurred market growth. These vaccines are highly effective at preventing or mitigating the severity of herpes zoster and have become a standard preventive measure, especially among older adults who are at the greatest risk of infection. Furthermore, ongoing research and development efforts are continually uncovering new treatment modalities, including potential antiviral targets and innovative pain management strategies. These advancements hold promise for improving the overall care and quality of life for individuals affected by herpes zoster.

Key Market Challenges

High Treatment Costs

The Global Herpes Zoster Infection Treatment Market has witnessed substantial growth in recent years due to various factors, but one significant challenge that hampers its progress is the high cost of treatment. Herpes zoster, commonly known as shingles, is a painful viral infection caused by the reactivation of the varicella-zoster virus, the same virus responsible for chickenpox. While effective treatments are available, their cost can be prohibitive for many patients, resulting in delayed or inadequate care.

The cost of herpes zoster infection treatment encompasses several components, including antiviral medications, pain management drugs, and vaccines. Antiviral medications like acyclovir, valacyclovir, and famciclovir are crucial for reducing the severity and duration of shingles symptoms. However, these medications often come with a high price tag, making them inaccessible to a significant portion of the population, particularly those without comprehensive healthcare coverage.

Pain management is another critical aspect of herpes zoster treatment. The excruciating pain and discomfort associated with shingles require medications such as opioids and anti-inflammatory drugs. These drugs can also be expensive, adding to the overall treatment costs. Furthermore, innovative pain management techniques and therapies, while effective, may not be readily available or covered by insurance plans, further increasing the financial burden on patients.

Limited Access to Healthcare

The Global Herpes Zoster Infection Treatment Market has been on a growth trajectory in recent years, driven by various factors. However, a significant challenge that hinders its expansion is the limited access to healthcare services, particularly in developing and underserved regions. Herpes zoster, commonly known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus, and its effective treatment relies on timely medical intervention.

In many parts of the world, individuals still struggle to access even basic healthcare services, let alone specialized treatments for conditions like herpes zoster. This lack of access to healthcare facilities and healthcare professionals can lead to delayed diagnosis and inadequate management of herpes zoster infections, ultimately affecting treatment outcomes.

The consequences of limited access to healthcare are particularly pronounced in the context of herpes zoster. The condition often presents with a painful rash and blisters, and prompt diagnosis and treatment are essential to reduce the severity of symptoms and prevent complications such as postherpetic neuralgia (PHN), a chronic pain condition that can persist long after the rash has healed.

Moreover, access to essential medications for herpes zoster, such as antiviral drugs and pain management medications, can be challenging in areas with limited healthcare infrastructure. Patients in these regions may find it difficult to obtain the necessary medications or may face high costs associated with them, further deterring them from seeking treatment.

Key Market Trends

Expanding Access to Healthcare

Expanding access to healthcare services has emerged as a significant catalyst in boosting the Global Herpes Zoster Infection Treatment Market. Herpes zoster, commonly known as shingles, is a painful viral infection caused by the reactivation of the varicella-zoster virus, and access to timely medical care is crucial for effective treatment. As healthcare systems evolve and become more accessible in various parts of the world, individuals are increasingly able to receive the necessary diagnostic and treatment options for herpes zoster, driving market growth.

In many regions, improving healthcare infrastructure and services has been a top priority for governments and healthcare organizations. Investments have been made to establish clinics, hospitals, and primary care centers even in underserved areas, ensuring that individuals have proximity to healthcare facilities. This enhanced accessibility has enabled individuals experiencing the symptoms of shingles to seek medical attention promptly, leading to timely diagnosis and intervention.

Furthermore, telemedicine and telehealth services have played a pivotal role in expanding access to healthcare for herpes zoster patients. Telemedicine allows individuals to consult with healthcare professionals remotely, reducing the barriers of distance and travel. Patients can receive timely advice, diagnosis, and prescriptions, improving the overall management of herpes zoster infections.

The expansion of healthcare access has also led to more widespread awareness about herpes zoster and the importance of early diagnosis and treatment. As individuals become better informed about the condition and its potential complications, they are more likely to seek medical care when they experience symptoms. This proactive approach not only benefits individual patients but also contributes to the overall growth of the herpes zoster infection treatment market. Moreover, initiatives undertaken by governments and non-governmental organizations to subsidize healthcare costs or provide financial assistance programs have further improved access to treatment for herpes zoster. These programs aim to reduce the financial burden on patients, ensuring that even those with limited financial resources can receive essential medications and vaccines.

High Economic Burden

The high economic burden associated with herpes zoster infection has been a significant factor in boosting the Global Herpes Zoster Infection Treatment Market. Herpes zoster, more commonly known as shingles, not only imposes a considerable physical and emotional toll on patients but also results in substantial healthcare costs and economic losses. This economic burden has prompted increased investments in research, development, and treatment options, further propelling the market's growth.

Beyond the direct healthcare costs, shingles also inflicts indirect economic burdens. The severity of symptoms can result in individuals taking time off work, leading to lost productivity and wages. In some cases, the pain and discomfort associated with shingles can be so debilitating that it hinders individuals from performing their daily activities, including work-related duties. The indirect costs stemming from reduced productivity and absenteeism can be substantial for both individuals and employers.

These economic implications have spurred pharmaceutical companies and researchers to invest in the development of more effective treatments and preventive measures for herpes zoster. The market has seen the introduction of antiviral medications, pain management drugs, and vaccines, all designed to reduce the severity of symptoms, mitigate complications, and lessen the overall economic burden of shingles.

Furthermore, public health organizations and healthcare providers have emphasized the importance of vaccination as a cost-effective strategy for preventing herpes zoster and its associated complications. Vaccines like Zostavax and Shingrix have been instrumental in reducing the incidence of shingles and, subsequently, the economic burden it places on healthcare systems.

Segmental Insights

Treatment Type Insights

Based on the Treatment Type, the Prescription treatment emerged as the dominant segment in the global market for Global Herpes Zoster Infection Treatment Market in 2022. Prescription treatments for herpes zoster, including antiviral medications (such as acyclovir, valacyclovir, and famciclovir) and targeted therapies, have been clinically proven to be highly effective in reducing the severity and duration of the infection. They are specifically designed to target the varicella-zoster virus responsible for herpes zoster, helping to control its replication and spread within the body.

Distribution Channel Insights

Based on the Distribution Channel, the Retail pharmacies emerged as the dominant player in the global market for Global Herpes Zoster Infection Treatment Market in 2022 Retail pharmacies are easily accessible to the general population. They are typically located in urban and suburban areas, making it convenient for patients to visit and obtain their prescribed medications. This accessibility ensures that individuals have a nearby source for herpes zoster infection treatments.

Retail pharmacies have a long-established presence in the healthcare landscape, and people are familiar with their services. Patients often have established relationships with pharmacists and trust the expertise and guidance they provide, which is particularly important for a condition like herpes zoster.

Regional Insights

North America emerged as the dominant player in the global Herpes Zoster Infection Treatment Market in 2022, holding the largest market share. North America, particularly the United States and Canada, has a significant aging population. As individuals age, their immune systems weaken, making them more susceptible to conditions like herpes zoster (shingles). The demographic shift toward an older population has led to a higher prevalence of herpes zoster cases in the region.

North America boasts well-developed healthcare infrastructure and a high level of healthcare awareness among both healthcare professionals and the general public. This awareness leads to early diagnosis and appropriate treatment for herpes zoster cases, driving the demand for treatment options..

Key Market Players

GSK plc.

Bausch Health Companies Inc.

Renata Limited

Novan, Inc.

Teva Pharmaceuticals USA, Inc.

Pfizer Inc.

Apotex Inc.

Sandoz Canada Inc.

Novartis Pharmaceuticals Corporation

Report Scope:

In this report, the Global Herpes Zoster Infection Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Herpes Zoster Infection Treatment Market, By Treatment Type:

• Primary
• Secondary
• Congenital
• Developmental

Global Herpes Zoster Infection Treatment Market, By Route of administration:

• Oral
• Intravenous
• Others

Global Herpes Zoster Infection Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Herpes Zoster Infection Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Herpes Zoster Infection Treatment Market.

Available Customizations:

• Global Herpes Zoster Infection Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Herpes Zoster Infection Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment Type (Prescription Treatment, Supporting Treatment)
  • 4.2.2. By Route of Administration (Oral, Intravenous, Others)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Treatment Type
  • 4.3.2. By Treatment
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Herpes Zoster Infection Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type
  • 5.2.2. By Route of Administration
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Herpes Zoster Infection Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment Type
      • 5.3.1.2.2. By Treatment
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Herpes Zoster Infection Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment Type
      • 5.3.2.2.2. By Route of Administration
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Herpes Zoster Infection Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment Type
      • 5.3.3.2.2. By Route of Administration
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Herpes Zoster Infection Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment Type
      • 5.3.4.2.2. By Route of Administration
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Herpes Zoster Infection Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment Type
      • 5.3.5.2.2. By Route of Administration
      • 5.3.5.2.3. By Distribution Channel

6. Europe Herpes Zoster Infection Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Herpes Zoster Infection Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Herpes Zoster Infection Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Herpes Zoster Infection Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Herpes Zoster Infection Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment Type
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Herpes Zoster Infection Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment Type
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. North America Herpes Zoster Infection Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Route of Administration
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Herpes Zoster Infection Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Herpes Zoster Infection Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Herpes Zoster Infection Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel

8. South America Herpes Zoster Infection Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Herpes Zoster Infection Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Herpes Zoster Infection Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Herpes Zoster Infection Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Herpes Zoster Infection Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Herpes Zoster Infection Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Herpes Zoster Infection Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Herpes Zoster Infection Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. Egypt Herpes Zoster Infection Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment Type
      • 9.3.4.2.2. By Route of Administration
      • 9.3.4.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Iron Deficiency Anemia: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. GSK plc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Bausch Health Companies Inc.
• 14.3. Renata Limited
• 14.4. Novan, Inc.
• 14.5. Teva Pharmaceuticals USA, Inc.
• 14.6. Pfizer Inc.
• 14.7. Apotex Inc.
• 14.8. Sandoz Canada Inc.
• 14.9. Novartis Pharmaceuticals Corporation.

15. Strategic Recommendations

16. About Us & Disclaimer